90% of it was off label in an observational study at Duke reported in an abstract presentation at ASH 2010. (Via Medpage Today).
Although the drug is expensive, at over 3 grand for the average patient, there was a suggestion that it might reduce costs overall in that it markedly decreased the use of other blood products.
No comments:
Post a Comment